The frequency of monocytic/macrophage cells (defined as SSChighCD45highHLA-DR+) presenting the M2 marker, CD36, in AML primary samples was higher in patients with high ME1 expression (Figure 5B). This evidence concerns the gene ME1 and acute myeloid leukemia.